Making anticoagulation safer.
作者信息
Gailani David
机构信息
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
出版信息
Lancet. 2022 Apr 9;399(10333):1360-1361. doi: 10.1016/S0140-6736(22)00563-3. Epub 2022 Apr 3.
Abstract
摘要
相似文献
1
Making anticoagulation safer.让抗凝治疗更安全。
Lancet. 2022 Apr 9;399(10333):1360-1361. doi: 10.1016/S0140-6736(22)00563-3. Epub 2022 Apr 3.
2
3
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.新型口服抗凝药用于房颤患者卒中预防的成本效益：取决于华法林抗凝控制的质量
Pharmacoeconomics. 2015 Apr;33(4):395-408. doi: 10.1007/s40273-014-0246-7.
4
Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics.将直接口服抗凝剂的综合管理纳入抗凝门诊。
Pharmacotherapy. 2017 Oct;37(10):1284-1297. doi: 10.1002/phar.1991. Epub 2017 Sep 6.
5
Emergency reversal of warfarin anticoagulation.华法林抗凝的紧急逆转
CMAJ. 2010 Dec 14;182(18):2004. doi: 10.1503/cmaj.100983. Epub 2010 Nov 15.
6
Exploiting common genetic variation to make anticoagulation safer.利用常见基因变异使抗凝治疗更安全。
Stroke. 2009 Mar;40(3 Suppl):S64-6. doi: 10.1161/STROKEAHA.108.533190. Epub 2009 Jan 15.
7
Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.与华法林相比，直接口服抗凝剂所致脑出血的体积及特征
Cerebrovasc Dis Extra. 2017;7(1):62-71. doi: 10.1159/000462985. Epub 2017 Apr 3.
8
Reversible endotension associated with excessive warfarin anticoagulation.与华法林抗凝过度相关的可逆性血管内张力
J Vasc Surg. 2007 Mar;45(3):600-2. doi: 10.1016/j.jvs.2006.10.044.
9
Pharmacogenomics of anticoagulation therapy: the last 10 years.抗凝治疗的药物基因组学：过去十年
Pharmacogenomics. 2019 Nov;20(16):1113-1117. doi: 10.2217/pgs-2019-0149.
10
Interhospital Transfer Delays Anticoagulation Reversal in Warfarin-Associated Intracranial Hemorrhage.医院间转运延迟对华法林相关颅内出血抗凝逆转的影响
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3345-3349. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.045. Epub 2018 Aug 30.
引用本文的文献
1
Thrombolytic therapy of human black hair and Au drug-loaded nanocapsules in vivo and in vitro based on near infrared II laser response.基于近红外II激光响应的人黑发与载金药物纳米胶囊的体内外溶栓治疗
J Mater Sci Mater Med. 2025 Jul 30;36(1):62. doi: 10.1007/s10856-025-06910-6.
2
Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease.凝血因子XI抑制剂是治疗与年龄相关血栓性疾病的新型有前景的抗凝剂。
Front Cardiovasc Med. 2025 May 30;12:1498826. doi: 10.3389/fcvm.2025.1498826. eCollection 2025.
3
Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.阿贝西单抗用于癌症相关血栓形成：在正确的时间为正确的目的使用正确的药物。全面综述。
Rev Cardiovasc Med. 2023 Oct 19;24(10):295. doi: 10.31083/j.rcm2410295. eCollection 2023 Oct.
4
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗患者的出血并发症
Rev Cardiovasc Med. 2022 Aug 15;23(8):286. doi: 10.31083/j.rcm2308286. eCollection 2022 Aug.
5
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.作为新型抗凝靶点的凝血因子XIa抑制剂：近期临床研究进展
Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. doi: 10.3390/ph16060866.
6
Hemostasis in neonatal ECMO.新生儿体外膜肺氧合中的止血
Front Pediatr. 2022 Aug 26;10:988681. doi: 10.3389/fped.2022.988681. eCollection 2022.
本文引用的文献
1
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.口服因子 XIa 抑制剂 asundexian 与房颤患者的阿哌沙班（PACIFIC-AF）相比的安全性：一项多中心、随机、双盲、双模拟、剂量发现的 2 期研究。
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
2
Milvexian for the Prevention of Venous Thromboembolism.密尔沃基用于预防静脉血栓栓塞。
N Engl J Med. 2021 Dec 2;385(23):2161-2172. doi: 10.1056/NEJMoa2113194. Epub 2021 Nov 15.
3
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week.因子 XI 抑制：将血栓形成与止血分离——JACC 本周综述专题。
J Am Coll Cardiol. 2021 Aug 10;78(6):625-631. doi: 10.1016/j.jacc.2021.06.010.
4
Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.利伐沙班和华法林对房颤患者胃肠道出血和颅内出血风险的影响：系统评价和荟萃分析。
Clin Cardiol. 2021 Sep;44(9):1208-1215. doi: 10.1002/clc.23690. Epub 2021 Jul 24.
5
Abelacimab for Prevention of Venous Thromboembolism.Abelacimab 用于预防静脉血栓栓塞。
N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19.
6
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.奥索司他单抗预防膝关节置换术患者静脉血栓栓塞的效果：FOXTROT 随机临床试验。
JAMA. 2020 Jan 14;323(2):130-139. doi: 10.1001/jama.2019.20687.
7
An update on factor XI structure and function.因子 XI 结构与功能的最新研究进展。
Thromb Res. 2018 Jan;161:94-105. doi: 10.1016/j.thromres.2017.10.008. Epub 2017 Oct 10.
8
Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events.因子 XI 缺乏与心血管和静脉血栓栓塞事件的风险降低相关。
Blood. 2017 Mar 2;129(9):1210-1215. doi: 10.1182/blood-2016-09-742262. Epub 2016 Dec 30.
9
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者时的非大出血情况比较
Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24.
10
Factor XI antisense oligonucleotide for prevention of venous thrombosis.XI 因子反义寡核苷酸预防静脉血栓形成。
N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.
Zotero 插件